Global Perspectives on Acute Lymphocytic Leukemia (ALL) in 2023 and Beyond – Focus on Combination Therapies

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding acute lymphocytic leukemia

December 1, 2023


Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA


Gail J. Roboz, MD

Weill Cornell Medicine, New York, NY, USA


Aaron Logan, MD, PhD
University of California, San Francisco, CA, USA

Ibrahim Aldoss, MD
City of Hope, Duarte, CA, USA

Wendy Stock, MD
University of Chicago, Chicago, IL, USA

Andre Schuh, MD, FRCPC
Princess Margaret Cancer Centre, Toronto, ON, Canada

Selina Luger, MD
University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Daniel J. DeAngelo, MD, PhD
Harvard Medical School, Boston, MA, USA

Tobias Menne, MD, PhD
Newcastle upon Tyne Hospitals, United Kingdom

Nicolas Boissel, MD, PhD
Hôpital Saint-Louis, Paris, France

Nicola Gökbuget, MD
University Hospital Frankfurt, Germany

Renato Bassan, MD
Ospedale dell’Angelo and Ospedale SS, Venice, Italy

Shaun Fleming, MBBS (Hons), FRACP, FRCPA
Melbourne Haematology, Richmond, VIC, Australia

Sample Report

Start discovering the insights

View Report


  • Blinatumomab in First Line and Maintenance for ALL
  • Backbone Therapies for First-Line AYA ALL
  • Backbones for First-Line Ph-Positive ALL
  • Backbones for First-Line Ph-Negative ALL – Transplant Ineligible
  • Backbones for First-Line Ph-Negative ALL – Transplant Eligible

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.